AstraZeneca: Fasenra Approved By FDA To Treat Eosinophilic Granulomatosis With Polyangiitis
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
PharmiWeb1d
Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
EuropaWire2d
FDA Approves AstraZeneca’s Fasenra for Eosinophilic Granulomatosis with Polyangiitis, Offering New Hope for Patients
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...
Daily1d
FDA approves Benralizumab for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
AstraZeneca (LSE:AZN) Gains FDA Approval for Fasenra in EGPA, Boosting Revenue Growth and Market Position
AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
Managed Healthcare Executive2d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
FiercePharma2d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...
pulmonologyadvisor1d
FDA Approves Fasenra for Eosinophilic Granulomatosis With Polyangiitis
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
EuropaWire2d
Tag Archives: Fasenra
(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated vasculitis that can be ...